Pharmaceutical

Kymera’s novel MDM2 degrader granted orphan designation for AML

Kymera Therapeutics has announced that the FDA has granted KT-253 orphan drug designation for treating acute myeloid leukaemia.

Jun 23, 2023 - 20:00
Kymera’s novel MDM2 degrader granted orphan designation for AML
Kymera Therapeutics has announced that the FDA has granted KT-253 orphan drug designation for treating acute myeloid leukaemia.
Read the original article

Tags:

Previous Article

Talaris Therapeutics to merge with Tourmaline Bio

Next Article

Coherus Expands Beyond Biosimilars with $65M Acquisition

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: With new trial data, a blockbuster therapy from Sanofi, Regeneron could find an even bigger market

STAT+: With new trial data, a blockbuster therapy from ...

Nov 27, 2023

STAT+: Dana-Farber’s divorce from Brigham is the culmination of decades of change

STAT+: Dana-Farber’s divorce from Brigham is the culmin...

Oct 16, 2023

MSD mulls 2025/26 launch for RSV vaccine after Phase II/III win

MSD mulls 2025/26 launch for RSV vaccine after Phase II...

Oct 20, 2024